Determination of leukemia stem cells in childhood acute myeloid leukemia and its clinical significance.
- Author:
Di WANG
1
;
Yong-Min TANG
;
Xiao-Jun XU
;
Hong-Qiang SHEN
;
Bai-Qin QIAN
Author Information
1. Department of Hematology and Oncology, Children Hospital, Zhejiang University Medicial College, Hangzhou 310003, Zhejiang Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Child;
Child, Preschool;
Female;
Flow Cytometry;
Humans;
Immunophenotyping;
Leukemia, Myeloid, Acute;
immunology;
metabolism;
Male;
Neoplasm, Residual;
immunology;
metabolism;
Neoplastic Stem Cells;
cytology;
Tumor Stem Cell Assay
- From:
Journal of Experimental Hematology
2010;18(4):952-958
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to detect the presence of human AML leukemia stem cells (LSC) in childhood patients with acute leukemia (AL) and analyze the correlation between LSC concentrations and minimal residual disease (MRD) levels in AML cases after remission. The multi-parameter flow cytometry (FCM) and a panel of monoclonal antibody combination were used to detect the AML LSC or AML LSC immunophenotype-identical cell (AML LSC-IPIC) concentrations in childhood AML or ALL leukemia both at new diagnosis and at remission and correlated AML LSC to the MRD levels at different time points after remission. The results indicated that the AML LSC or AML LSC-IPIC concentrations [in average 166 (range 14 - 1459)/100 000 mononuclear cells (MNCs)] in AML at initial diagnosis were significantly higher than those in ALL [7 (range 0 - 560)/100 000 MNCs, p < 0.017] and control [0 (range 0 - 6)/100 000 MNCs, p < 0.017], respectively. The AML LSC concentrations in AML at non-CR were in average 36 (range 5 - 224)/100 000 MNCs. No statistical difference (p > 0.05) was found between the AML LSC or AML LSC-IPIC concentrations in AML (in average 6 (range 0 - 41)/100, 000 MNCs) and ALL [10 (range 0 - 105)/100, 000 MNCs] after CR. The significantly negative correlation was noticed between AML LSC concentrations and MRD levels. It is concluded that the AML LSCs exist in newly diagnosed AML, which are significantly reduced when complete remission has achieved, but the low levels of these populations still remain. The phenotypically similar (CD34(+)CD38⁻CD123(+)) AML LSC populations have also been found in the bone marrow from ALL patients, but their concentrations are not significantly different when CR has achieved. The significantly negative correlation between AML LSC concentrations and MRD levels is observed in AML patients after remission.
